CYP3A4 and breast carcinoma: In conclusion, this study demonstrates that among women receiving adjuvant chemotherapy for breast cancer, a polymorphism in the cyclophosphamide-metabolizing enzyme CYP3A4 independently contributes to outcomes from cyclophosphamide-based adjuvant breast cancer chemotherapy.